Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

NCT00195702 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

NCT00538902 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

NCT00647920 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis

NCT00195819 ·Status: COMPLETED ·Phase: PHASE3

Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

NCT00646386 ·Status: COMPLETED ·Phase: PHASE2

A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing Spondylitis

NCT01901627 ·Status: UNKNOWN

The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients

NCT05527444 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

NCT00085644 ·Status: COMPLETED ·Phase: PHASE3

Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

NCT06833112 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects

NCT03357939 ·Status: COMPLETED ·Phase: PHASE1

Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab

NCT00650390 ·Status: APPROVED_FOR_MARKETING

Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis

NCT00650156 ·Status: COMPLETED ·Phase: PHASE1

A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China

NCT01464021 ·Status: TERMINATED

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

NCT00646178 ·Status: COMPLETED ·Phase: PHASE3

Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate

NCT00235859 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

NCT01225393 ·Status: COMPLETED ·Phase: PHASE2

Real World Study of a Adalimumab Biosimilar (Geleli) in Rheumatoid Arthritis

NCT05240859 ·Status: UNKNOWN

A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia

NCT01387789 ·Status: COMPLETED

A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

NCT02955212 ·Status: COMPLETED ·Phase: PHASE3

Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)

NCT01064856 ·Status: COMPLETED ·Phase: PHASE3

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

NCT00647270 ·Status: COMPLETED ·Phase: PHASE3

Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

NCT03486457 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

NCT00235885 ·Status: COMPLETED ·Phase: PHASE3

Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis

NCT00649922 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

NCT01077258 ·Status: COMPLETED